BamSEC and AlphaSense Join Forces
Learn More

Oruka Therapeutics Inc. – Material Contracts

NASDAQ: ORKA    
Share price (6/2/26): $55.23    
Market cap (6/2/26): $3.331 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 5 pages First Amendment to Il-23 License Agreement
12/34/56
EX-10.9
from 10-K 6 pages Oruka Therapeutics, Inc. 2024 Stock Incentive Plan Grant Notice for Restricted Stock Unit Award
12/34/56
EX-10.1
from 8-K 2 pages Offer Letter, Dated December 1, 2025, Between Oruka Therapeutics, Inc. and Chris Martin
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 10 pages Offer Letter, Dated July 1, 2025, Between Oruka Therapeutics, Inc. and Laura Sandler.
12/34/56
EX-10.33
from 10-K 2 pages Amendment No. 1 to the Cell License Agreement
12/34/56
EX-10.32
from 10-K 14 pages Cell Line License Agreement
12/34/56
EX-10.31
from 10-K 43 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Il-23 License Agreement
12/34/56
EX-10.29
from 10-K 40 pages Definitions
12/34/56
EX-10.20
from 10-K 1 page Oruka Therapeutics, Inc. Non-Employee Directors Compensation Program
12/34/56
EX-10.19
from 10-K 10 pages Indemnification Agreement
12/34/56
EX-10.18
from 10-K 11 pages October 1, 2024 3. Bonus Compensation
12/34/56
EX-10.17
from 10-K 11 pages Amended and Restated Employment Letter Agreement by and Between Oruka Therapeutics, Inc. and Paul Quinlan, Dated October 1, 2024
12/34/56
EX-10.4
from 10-Q 20 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 10 pages Amended and Restated Employment Letter Agreement by and Between the Company and Arjun Agarwal, Dated as of October 3, 2024
12/34/56
EX-10.1
from 8-K 10 pages Amended and Restated Employment Letter Agreement by and Between the Company and Dr. Lawrence Klein, Dated as of October 3, 2024
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 64 pages Securities Purchase Agreement
12/34/56
EX-10.25
from 8-K 10 pages Consulting Agreement
12/34/56